Jahan H, Akhter F, Nandi A K
Dr Hasna Jahan, Assistant Professor, Army Medical College Bogura, Bogura, Bangladesh; E-mail:
Mymensingh Med J. 2020 Apr;29(2):414-419.
Urticaria is a common clinical condition that gives a major concern for physicians and patients alike. Urticaria is referred to as chronic when wheals occur daily or almost daily for a period of at least six weeks. The primary purpose of this study is to find out the efficacy of fexofenadine in the treatment of chronic idiopathic urticaria patients among the Bangladeshi population. This quasi-experimental study was performed in the Department of Dermatology & Venereology, Shaheed Ziaur Rahman Medical College Hospital, Bogura, Bangladesh from July 2013 to December 2013. Total 100 patients of chronic idiopathic urticaria aged 18 years and above with exclusion and inclusion criteria were selected. Then they were given fexofenadine 120mg twice daily for the treatment of chronic idiopathic urticaria for four weeks. A semi quantitative rating scales were used for the assessment of therapeutic efficacy before and after treatment. Data were collected in a pre-designed questionnaire by face-to-face interview and analyzed by the help of SPSS. Among the 100 respondents after one week of treatment, 8.0% had complete disappearance of symptoms, 10.0% had marked improvement, 40.0% had moderate improvement and 42.0% had slight improvement. After two weeks of treatment 35.0% had complete disappearance of symptoms, 13.0% had marked improvement, 12.0% had moderate improvement and 40.0% had slight improvement. After three weeks of treatment 40.0% had complete disappearance of symptoms, 13.0% had marked improvement, 35.0% had moderate improvement and 12.0% had slight improvement. After four weeks of treatment 42.0% had complete disappearance of symptoms, 24.0% had marked improvement, 26.0% had moderate improvement and 8.0% had slight improvement. The study concluded that fexofenadine is very effective in the treatment of chronic idiopathic urtecaria.
荨麻疹是一种常见的临床病症，同样引起医生和患者的高度关注。当风团每天或几乎每天出现，且持续至少六周时，荨麻疹被称为慢性荨麻疹。本研究的主要目的是了解非索非那定在治疗孟加拉人群慢性特发性荨麻疹患者中的疗效。这项准实验研究于2013年7月至2013年12月在孟加拉国博古拉的谢赫·齐亚乌尔·拉赫曼医学院医院皮肤科与性病科进行。总共挑选了100名年龄在18岁及以上、符合排除和纳入标准的慢性特发性荨麻疹患者。然后给予他们非索非那定120毫克，每日两次，用于治疗慢性特发性荨麻疹，为期四周。使用半定量评分量表评估治疗前后的疗效。通过面对面访谈，在预先设计的问卷中收集数据，并借助SPSS进行分析。在100名受访者中，治疗一周后，8.0%的患者症状完全消失，10.0%的患者有显著改善，40.0%的患者有中度改善，42.0%的患者有轻微改善。治疗两周后，35.0%的患者症状完全消失，13.0%的患者有显著改善，12.0%的患者有中度改善，40.0%的患者有轻微改善。治疗三周后，40.0%的患者症状完全消失，13.0%的患者有显著改善，35.0%的患者有中度改善，12.0%的患者有轻微改善。治疗四周后，42.0%的患者症状完全消失，24.0%的患者有显著改善，26.0%的患者有中度改善，8.0%的患者有轻微改善。该研究得出结论，非索非那定在治疗慢性特发性荨麻疹方面非常有效。
